PIK3CB and neoplasm: After two decades of research into the clinical translatablility of PI3K pathway inhibitors, it is reasonable to state that despite modest clinical activity in solid tumours PI3K inhibitors have the potential to be important pharmacological compounds for the treatment of these tumours.